Takeda announced that TAK-003its experimental dengue vaccine, managed to prevent 84% of dengue cases requiring hospitalization for dengue and 61% of symptomatic cases, with no significant safety risks identified in the general population including seropositive and seronegative individuals for a period of time 4 and a half years (54 months) post vaccination.
This, according to a pivotal phase 3 clinical trial called TIDES (Efficacy Study of Tetravalent Immunization against Dengue).
It should be remembered that dengue is the viral disease transmitted by a mosquito with the fastest spread and was included in the ranking of the 10 main threats to global public health according to the WHO in 2019.
The dengue It is transmitted mainly by the Aedes aegypti mosquito and, to a lesser extent, by the Aedes albopictus.
–
